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Chemotherapy liverAbstract Purpose: To evaluate the role of multi-detector computed tomography (MDCT) in
detection and characterization of chemotherapy induced hepatic changes.
Materials and methods: This retrospective study included 400 patients with conﬁrmed 14
malignancies and treated by standard chemotherapy regimens. The most common malignancy
was non-Hodgkin lymphoma and mostly chemotherapy regimen was Cyclophosphamide,
Hydroxydaunomycin, Oncovin and Prednisolone (CHOP). All patients underwent CT scan using
64 MDCT scanner (Brilliance 64, Philips) before chemotherapy and follow-up after 6 months from
last session of chemotherapy. Precontrast series and post-contrast triphasic study were done for all
patients. All the patients underwent radiological evaluation for hepatic changes after chemotherapy
treatment. All CT scans were evaluated for fatty liver, capsular retraction, venoocclusive disease
and biliary sclerosis. Four patients with capsular retraction underwent liver biopsy.
Results: Forty patients (32 females and 8 males) had hepatic changes due to effect of chemother-
apy. The most common CT ﬁnding was fatty liver. Hepatic fatty changes were detected in 36/40
patients. These fatty changes were diffuse, focal fatty and diffuse with fatty spare area. Four
patients had capsular retraction: 1 patient with HD and 3 patients with metastatic cancer breast.
Veno-occlusive disease and biliary sclerosis were not detected.
 2016 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).(A. El-
Halim),
Table 2 The distribution of primary tumors according to
patient sex.
Primary lesion Distribution according to
sex of the patient
Total
Male Female
NHL 134 100 234 (58.5%)
HD 26 22 48 (12%)
Breast – 32 32 (8%)
Colon 8 6 14 (3.5%)
Ovary – 20 20 (5%)
Stomach 6 8 14 (3.5%)
Bladder 2 – 2 (0.5%)
Pancreas 12 6 18 (4.5%)
Esophagus – 2 2 (0.5%)
Germ cell 2 2 4 (1%)
CLL 2 2 4 (1%)
Osteosarcoma 2 – 2 (0.5%)
Neuroblastoma – 4 4 (1%)
Endometrial carcinoma – 2 2 (0.5%)
Total 194 206 400 (100%)
Table 3 Different chemotherapy regimens used in 400
patients.
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Chemotherapy as the main nonsurgical remedy of cancer treat-
ment is generally based on the cytotoxic effect of natural or
synthetic agents taking advantage of a higher vulnerability of
cancer cells as compared to normal cells. However, normal
cells may be affected by cytotoxic chemotherapy as well (1).
Cancer chemotherapy has evolved from cytotoxic agents
and now includes several new agents that target speciﬁc mole-
cules responsible for the regulation of cell growth, nutrient
supply, and differentiation. These molecularly targeted thera-
pies have a different mechanism of action than do classic cyto-
toxic agents, which predominantly attack rapidly proliferating
cells. Therefore, the toxicities of targeted and cytotoxic agents
may differ in both clinical and radiological presentations (2).
The ﬁnal effect of all these drugs is to inhibit cell division in
rapidly dividing cells and thereby reduce the cell turnover in
cancer tissues. Unfortunately, these drugs can also affect the
normal cells, especially those with rapid cell division, leading
to signiﬁcant complications. That is why the GIT and bone
marrow are more susceptible to injury in patients undergoing
cytotoxic chemotherapy. However, it may affect any organ
in the body (3).
Chemotherapy related hepatic complications are relatively
common. The spectrum of pathology ranges from reversible
hepatic steatosis to advanced cirrhosis and vascular injury (4).
The purpose of this study was to evaluate the role of
MDCT in detection and evaluation of chemotherapy induced
hepatic changes, differentiation of these changes from progres-
sion of the disease and/or super added pathology.
2. Materials and methods
2.1. Patients
This study was approved by our institutional review board,
and informed consent was waived. This retrospective study
included 400 patients (206 females and 194 males). The com-
plaint of the 400 patients at time of presentation was variable
and ranged from loss of weight to palpable masses. Some of
these cases were complaining of more than one symptom.
The clinical presentations of the 400 patients are represented
in Table 1. These patients presented with 14 different malig-
nancies and were treated by standard systemic chemotherapyTable 1 Clinical presentation of 400 patients.
Clinical presentation No. of cases Percentage
Headache, nausea and vomiting 16 4
Neck swelling 36 9
Breast mass 32 8
Progressive loss of weight 264 66
Epigastric pain 32 8
Hematuria 2 0.5
Vaginal bleeding 2 0.5
Diﬃculty in swallowing 2 0.5
Constipation and abdominal distention 14 3.5
Total 400 100regimens without loco-regional chemotherapy between Jan-
uary 2014 and December 2015 (Tables 2 and 3).
Those patients were referred to perform abdominal CT
scans before and after chemotherapy regimens as follow-up
studies. All patients underwent three or more follow-up CT
scans from 1st session of chemotherapy. Laboratory evalua-
tion for liver function test, tumor markers, serum amylase
and serum creatinine was done.
2.2. MDCT imaging
All patients underwent precontrast and triphasic CT scan
using 64 multi-detector CT scanner (Brilliance 64; Philips
Healthcare, Best, Netherlands). The precontrast series was
taken by using a 5 mm slice thickness. Triphasic
post-contrast study was done using 120 ml of low osmolarChemotherapy regimen Number of cases
CHOP 196 Patients (49%)
DHAP 18 Patients (4.5%)
ABVD 34 Patients (8.5%)
FAC 32 Patients (8%)
ABVD+MINE 10 Patients (2.5%)
DHAP+MINE 6 Patients (1.5%)
ABVD+ CHOP 6 Patients (1.5%)
DHAP+ ICE 8 Patients (2%)
BEA-COPP 8 Patients (2%)
FOLFOX 12 Patients (3%)
ECF 8 Patients (2%)
CISPLATINE+ TAXANE 20 Patients (5%)
CISPLATINE+ GEMZAR 26 Patients (6.5%)
CISPLATINE+ 5-FLUROURACILE 8 Patients (2%)
CISPLATINE+ ENDOXANE 8 Patients (2%)
Total 400 (100%)
Table 4 Clinical presentation at time of diagnosis chemother-
apy complication.
Clinical
presentation
No. of
cases
Percentage from
aﬀected cases
Percentage
from total
cases
Asymptomatic 24 60 6
Easy fatigability
and loss of appetite
8 20 2
Abdominal pain 4 10 1
Abdominal
enlargement
4 10 1
Jaundice 0 0 0
Total 40 100 10
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rate of 5 ml/s; then, the CT scan was performed with the fol-
lowing acquisition parameters 200 mAs, 120 kVp, 512  512Table 5 The clinical data and the radiological ﬁndings for 40 cases
Primary tumor Hepatic radiological ﬁndings
Breast Car. Diﬀuse fatty
Breast Car. Capsular retraction/pseudo-cirrhosis
NHL Focal fatty inﬁltration
NHL Diﬀuse fatty
NHL Diﬀuse fatty
HD Diﬀuse fatty
HD Capsular retraction/pseudocirrhosis
Ovarian Car. Diﬀuse fatty
Pancreatic Car. Diﬀuse fatty
Colonic Car. Fatty liver with fatty sparing area
Acute ML Diﬀuse fatty
Endometrial Car. Diﬀuse fatty
Pat. No.: Patients’ Number.
NHL: Non-Hodgkin Lymphoma.
HD: Hodgkin Disease.
ML: Myeloid leukemia.
Car.: Carcinoma.
Fig. 1 44-Years-old female patient underwent mastectomy for canc
done. (A) Post oral and before IV contrast abdominal CT scan before
abdominal CT scan, 6 months after starting chemotherapy regimen
parenchyma).matrix, 1.172 pitch, 64  0.625 mm section collimation,
2 mm slice thickness, 1 mm reconstruction increment. All
images were transferred to the workstation [Extended Bril-
liance Workspace V3.5.0.2254] (EBW) for post processing.
2.3. Image analysis
Abdominal CT images were evaluated retrospectively using
Picture Archiving and Communication System (PACS, Paxer-
amed, Paxeramed Corp, Oslip, Austria) for all patients before
and after chemotherapy regimens to differentiate between pro-
gression of malignancy and chemotherapy changes.
The imaging analysis was based on source images. Data
interpretation was based on consensus of at least two radiolo-
gists with 15 years duration experience of abdominal imaging.
The precontrast images were used to measure the liver attenu-
ation index (LAI) by inserting multiple ROI in the liver and
spleen avoiding major vessels. Fatty inﬁltration of the liver is
diagnosed if the difference between average liver attenuation.
Chemotherapy Chem./Dose Pat. No.
FAC 6 Cycles 7
FAC 8 Cycles 3
CHOP 5 Cycles 3
CHOP 8 Cycles 5
CHOP 4 Cycles 8
ABVD 6 Cycles 2
CHOP 6 Cycles 1
Endoxan & platinol 4 Cycles 4
GEMZAR 7 Cycles 2
FOLFOX 3 Cycles 2
CHOP 4 Cycles 2
Cisplatin/Taxol 6 Cycles 1
40
er breast and received 6 cycles of FAC. Abdominal CT scan was
starting chemotherapy regimen which is normal. (B) Non-contract
which revealed diffuse hepatic fatty inﬁltration (hypodense liver
Fig. 3 70-Years-old female with colonic carcinoma received 3
cycles of FOLFOX. Triphasic CT scan was done. (A) (Late
arterial phase) before starting chemotherapy regimen which
revealed normal liver and spleen. (B) (Late arterial phase)
6 months after starting chemotherapy regimen which revealed
enlarged and diffuse hypodense liver parenchyma (lower than the
spleen) sparing small area of left liver lobe (fat sparing area);
enlarged spleen was also noticed.
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10 HU on non-enhanced scans. Liver attenuation index
(LAI) is deﬁned as the difference between mean hepatic and
mean splenic attenuation (5,6).
Post-contrast abdominal CT scans were used to detect
response to treatment (regression or progression) differentiat-
ing this from chemotherapy induced hepatic changes such as
fatty liver, capsular retraction, veno-occlusive disease and bil-
iary sclerosis. Four patients with capsular retraction under-
went liver biopsy.
In patients with capsular retraction, measurements of the
depth of the retraction, if present, were obtained by measuring
the greatest distance from the hepatic capsule to its expected
course and perpendicular to a line through the hepatic capsule.
Follow-up abdominal CT scans after chemotherapy of the
400 patients were reviewed and compared with other CT
abdominal scans obtained before starting chemotherapy
regimes.
3. Results
From the 400 patients 290 patients showed no changes induced
by chemotherapy detected in their abdominal CT scans. The
other 110 patients were carefully re-evaluated, comparing ﬁnd-
ings detected in their abdominal CT scans with the clinical
data, laboratory investigations and pre-chemotherapy CT
scans to know whether these changes were related to the
chemotherapy or progression of the disease and/or superadded
pathology. Final results (by exclusion of other possibilities as
newly developed hepatic focal lesions even if with fatty
changes) conﬁrmed that only 40 patients (with a percentage
of 10% of total cases) reported to have changes in liver which
are indeed due to effect of chemotherapy. The most common
chemotherapy regimen used was CHOP and the most common
ﬁnding was fatty liver. The 40 patients were 32 females and 8
males. Their ages ranged from 40 years up to 70 years old.
Clinical observation of the 40 patients resulted in 24 patients
of them were asymptomatic and accidentally discovered during
routine follow- up by abdominal CT scans (Table 4). Eight
patients presented with easy fatigability and loss of appetite.
Eight patients present with abdominal pain and abdominal
enlargement.Fig. 2 43-Years-old female patient with NHL and received 6 cycles of CHOP. Abdominal CT scan was done. (A) Non-contrast
abdominal CT scan axial cut (A) before starting chemotherapy regimen which is normal. (B) Arterial phase abdominal CT scan 6 months
after starting chemotherapy regimen revealed focal fatty inﬁltration of right liver lobe (hypodense right liver lobe parenchyma).
Fig. 4 45-Years-old female patient underwent mastectomy for cancer breast and received 8 cycles of FAC. Abdominal CT scan was
done. (A) Portal phase before starting chemotherapy regimen revealed: multiple small hypodense lesions scattered all over the liver
(metastatic). (B) Delayed phase, 6 months after starting chemotherapy revealed: marked decrease size and number of metastatic lesions
with signiﬁcant capsular retraction which mimic cirrhosis (pseudo cirrhosis) and ascites.
Fig. 5 57-Years-old female with HD received 6 cycles of CHOP.
Triphasic abdominal CT scan was done. (A) (Portal phase) before
starting chemotherapy shows a non-enhancing focal lesion of
segment IV, biopsy revealed HD. (B) (Portal phase) obtained
6 months after starting of chemotherapy shows capsular retraction
of the liver. The size of the hepatic mass is markedly decreased.
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patients (Table 5). Fatty changes were diffuse (31 patients),
focal fatty (3 patients) and diffuse with fatty spare (2 patients)
(Figs. 1–3). Four patients had capsular retraction (Figs. 4 and
5). Capsular retraction ranged in depth from 2 mm in 1 patient
with HD to 10–13 mm in 3 patients with metastatic cancer
breast. Veno-occlusive disease and biliary sclerosis were not
detected.
4. Discussion
Cancer therapy has signiﬁcantly improved in the past few dec-
ades with development of various newer classes of cytotoxic
chemotherapy as well as novel, molecularly targeted
chemotherapy. However, both these treatments affect the
tumor as well as the normal tissues, lead to signiﬁcant toxicity.
These side effects range from mild to life threatening, and may
involve multiple organs. Imaging plays an important role in
the early identiﬁcation of such complications, which may allow
more effective patient management (3).
Advancements in imaging have led to recognition of radio-
logical features of previously unsuspected diseases. Occasion-
ally, imaging may also identify effects of treatments
instituted for these diseases. Consequently, MDCT plays a
critical role in the accurate diagnosis of a broad spectrum of
drug-induced complications in the abdomen, in both emergent
and nonemergent settings. Knowledge of the natural history,
clinical manifestations, and salient imaging features of these
entities is crucial to facilitate accurate clinical diagnosis in a
timely fashion (7).
As the center of metabolism, the liver is susceptible to a
wide array of drug-related injuries. Hepatic steatosis is the
most common among them. It may be seen in nearly 20% of
patients undergoing treatment with certain forms of
chemotherapy (8). Steatosis may progress to steatohepatitis,
characterized by additional evidence of inﬂammation and
ﬁbrosis.
On CT, fatty inﬁltration typically has a well-deﬁned, geo-
metric pattern. On unenhanced CT scan, the attenuation of
the liver will be lower than the spleen due to the deposition
of fat within the hepatocytes, and the Hounsﬁeld unit measure-
ment may be less than 40. Further, the intrahepatic vasculature
698 S.S. Abd-Allah et al.appears hyperattenuating against the liver parenchyma on
unenhanced CT scan in the presence of severe steatosis (9).
In our study we compared pre- and post-chemotherapy
abdominal CT studies and detect changes appeared on liver
which were not seen in pre-chemotherapy CT studies differen-
tiating them from disease progression. Liver parenchyma
appeared low attenuated than spleen in precontrast CT study.
In our study we detected diffuse fatty liver in 31 cases, focal
fatty inﬁltration in 3 cases and diffuse fatty liver with fatty
spare areas in 2 cases.
Our ﬁndings are in agreement with Shanbhogue et al. (7). In
our study, we detected fatty inﬁltration of the liver in 36/400
(9%) patients. Fatty inﬁltration was seen in different patterns
focal, diffuse and fat sparing. Biopsy was taken from equivocal
cases to conﬁrm diagnosis. The difference was between our
study and that of Peppercon et al. (8) due to selection of certain
forms of chemotherapy. But, in our study there is no selection
of chemotherapy.
Advanced stages of hepatocellular injury may rarely pro-
gress to cirrhosis or pseudo cirrhosis. Pseudocirrhosis, charac-
terized by marked distortion of architecture with dense ﬁbrosis
is typically seen with metastatic breast cancer or lymphoma
after prolonged chemotherapy, and chemotherapy for pancre-
atic cancer (10,11).
This was reported in our study in 3 cases with metastatic
breast cancer treated by 8 cycles of FAC and developed signif-
icant capsular retraction (pseudo cirrhosis). One case of HD
with hepatic focal lesion was treated by 6 cycles of CHOP
and developed mild capsular retraction adjacent to the lesion
which decreased in size.
Blachar et al. (12) stated that, cirrhosis manifests as shrun-
ken nodular liver with atrophic right and medial left lobes and
hypertrophy of caudate and lateral left lobes. Pseudo cirrhosis
appears similar to cirrhosis on imaging, and this was clear in 3
cases of our study.
Wide spread capsular retraction was found in 3/32 (9.4%)
cases of metastatic cancer breast underwent FAC. This is in
agreement with previous study (13) who found this ﬁnding in
10/91 (11%). Fennessy et al. found hepatic capsular retraction
in 50% of patients with hepatic metastases of cancer breast
(14). This difference from our study 3/32 is due to small num-
ber of our cases and different chemotherapeutic regimens.
The pathological results of 3 cases with signiﬁcant capsular
retraction revealed nodular regenerative hyperplasia which is
characterized by forming regenerative hepatic nodules with
compression and atrophy of intervening parenchyma but with-
out hepatic ﬁbrosis. This was in agreement with previous stud-
ies (3,15).
In our study, veno-occlusive disease and biliary sclerosis
were not detected as a complication of chemotherapy, and
these not coincide with previous results reported by Robinson
(10) who reported that these complications were seen after
direct infusion of chemotherapeutic agents inside hepatic
artery; this method was not used with patients included in
our study.
4.1. Conclusion
MDCT can accurately detect and evaluate chemotherapy
induced hepatic changes, differentiation of these changes fromprogression of the disease and/or super added pathology.
Fatty liver is the commonest hepatic induced changes. Aware-
ness of chemotherapy induced hepatic changes can help the
radiologist to detect these at early stages, which helps in appro-
priate management.
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